二氟尼柳是一种众所周知的治疗类风湿性关节炎的药物,骨关节炎,原发性痛经,还有结肠癌.该分子属于非甾体抗炎药(NSAID),因此具有严重的副作用,如心血管疾病的风险发展,肾损伤,和肝脏反应。最后的临床数据表明,二氟尼柳是公认的治疗心脏淀粉样变性的药物之一,具有与临床批准的tafamidis相似的生存益处。二氟尼柳可稳定运甲状腺素蛋白(TTR)四聚体,并防止单体和二聚体的错误折叠在心脏中形成淀粉样蛋白沉积物。为了避免二氟尼柳的严重副作用,已经开发了各种输送系统。在本次审查中,关注二氟尼盐装载输送系统的最新发展,其技术,释放配置文件,和有效性。
Diflunisal is a well-known drug for the treatment of rheumatoid arthritis, osteoarthritis, primary dysmenorrhea, and colon cancer. This molecule belongs to the group of nonsteroidal anti-inflammatory drugs (NSAID) and thus possesses serious side effects such as cardiovascular diseases risk development, renal injury, and hepatic reactions. The last clinical data demonstrated that diflunisal is one of the recognized drugs for the treatment of cardiac amyloidosis and possesses a survival benefit similar to that of clinically approved tafamidis. Diflunisal stabilizes the transthyretin (TTR) tetramer and prevents the misfolding of monomers and dimers from forming amyloid deposits in the heart. To avoid serious side effects of diflunisal, the various delivery systems have been developed. In the present
review, attention is given to the recent development of diflunisal-loaded delivery systems, its technology, release profiles, and effectiveness.